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Immunogenicity of variable regions of hepatitis C virus
proteins: selection and modification of peptide epitopes to
assess hepatitis C virus genotypes by ELISA
Marta Rodrı!guez-Lo! pez, Jose! Ignacio Riezu-Boj, Marta Ruiz, Carmen Berasain, Marı!a Pilar Civeira,
Jesu! s Prieto and Francisco Borra! s-Cuesta
Universidad de Navarra, Facultad de Medicina, Departamento de Medicina Interna, Apartado 177, Pamplona, Spain
The immunogenicity of variable regions of hepatitis C virus (HCV) proteins was studied by ELISA by
using 543 synthetic peptides from 120 variable regions and 90 sera from HCV-infected patients.
Some regions from certain genotypes were less immunogenic, or even non-immunogenic,
compared with their equivalents in other genotypes. However, the mean recognition of all peptides
from genotypes 1a, 1b and 3 by sera infected with genotypes 1a, 1b and 3, respectively, showed
no significant differences, suggesting a similar overall immunogenicity of variable regions from
these genotypes. Proteins NS4a, NS4b and NS5a were found to be the most immunogenic.
Recognition of individual peptides by the sera of infected patients showed that the humoral
response against HCV is patient-dependent. The work shows that 15-mer peptides may encompass
several B-cell epitopes. These epitopes may lie in slightly different positions in different genotypes.
Thirty-one percent of the 543 peptides were recognized by some of the 35 healthy donors. This
may be a reflection of the large number of antigens to which they had been exposed, but it may also
reflect a strategy of HCV to respond to immune pressure. After selection and modification, a set of
40 peptides was used to assess genotypes 1a, 1b, 1, 2 and 3 in the sera of HCV-infected patients,
with sensitivities of 34–1, 48–5, 68–8, 58–3 and 48–9% and specificities of 100, 99–1, 97–1, 99–5
and 99%, respectively. The overall sensitivity and specificity for the assessment of genotypes 1, 2
and 3 were 64 and 98%, respectively.
Introduction
Hepatitis C virus (HCV) is a highly prevalent virus
worldwide. Its prevalence in developed countries is around 1%
of the general population (Rall & Dienstag, 1995) and around
0–1–0–7% in blood donors (Shakil et al., 1995). This prevalence
may be as high as 6% in some regions of Africa and the Middle
East (Darwish et al., 1993). Since HCV is mainly transmitted via
blood, haemo-derivatives and haemodialysis, the main pop-
ulations at risk are drug addicts, the recipients of blood
transfusions and of haemodialysis (Alter, 1989), organ trans-
plants (Pereira et al., 1991) and tattoos (Ko et al., 1992) and
health-care personnel (Polish et al., 1993). Approximately 80%
of patients suffering from acute hepatitis C develop chronic
hepatitis (Lau et al., 1993) and 20–35% develop liver cirrhosis
(Alter, 1989). A significant proportion of chronic patients
develop hepatocellular carcinoma (Tsukuma et al., 1993).
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HCV was first identified and cloned by Choo et al. (1989).
This allowed the engineering of ELISA assays based on
recombinant proteins (Kuo et al., 1989) and synthetic peptides
(Berasain et al., 1993) and more recently on a combination of
recombinant proteins and synthetic peptides (Vrielink et al.,
1995). Soon after the first complete genome sequence of HCV
was reported (Choo et al., 1991), two other sequences from
Japanese isolates were published (Kato et al., 1990 ; Takamizawa
et al., 1991). Several types and subtypes of HCV have been
found in different geographical areas (Bukh et al., 1993). Today,
the most widely accepted classification of HCV genotypes is
that put forward by Simmonds et al. (1994), which allows the
definition of six virus types and a great number of subtypes.
The nucleotide sequence identity between types is around
66–69% and that between subtypes of the same type 77–80%,
whereas an identity of 91–98% is found between sequences of
the same virus subtype (Simmonds, 1995). HCV genotypes 1a,
1b, 2a, 2b and 3 are distributed worldwide, whereas types 4, 5
and 6 are found mainly in North and Central Africa, South
Africa and south-west Asia, respectively (Bukh et al., 1993).
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Table 1. Synthetic peptides used in this study
The table shows the location of each variable region selected for this study [name of protein and location
within the HCV sequence as given by Choo et al. (1991), accession number M62321]. The source of the
sequences for each genotype is also given ; the GenBank accession numbers or references are : 1, M62321 ;
2, M67463 ; 3, X53134 ; 4, D10749 ; 5, L23439 ; 6, M96362 ; 7, D90208 ; 8, M74814, 9, D13558 ; 10, D10687 ;
11, L02836 ; 12, D11168 ; 13, D10750 ; 14, D00944 ; 15, L16650 ; 16, D10075 ; 17, M95105 ; 18, M95103 ;
19, L16655 ; 20, D10077 ; 21, L16672 ; 22, D01221 ; 23, Tsukiyama-Kohara et al. (1991) ; 24, Simmonds et al.
(1993) (T0059) ; 25, D10650 ; 26, D17763 ; 27, D14063 ; 28, L16659 ; 29, D10115 ; 30, Simmonds et al. (1993)
(T0040) ; 31, D10078 ; 32, D10080. nd, Not done.
Source of sequence Source of sequence
No. HCV region 1a 1b 2a 2b 3 No. HCV region 1a 1b 2a 2b 3
1 Core 67–78 1 6 14 nd 26 61 NS4b 1930–1943 1 nd 14 nd nd
2 Core 156–165 1 nd nd nd 27 62 NS4b 1946–1959 1 7 14 22 26
3 E1 192–204 1 7 15 19 26 63 NS4b 1958–1971 1 7 14 22 26
4 E1 210–223 1 7 14 19 26 64 NS5a 1982–1995 1 6 14 22 26
5 E1 214–224 1 7 nd nd nd 65 NS5a 1996–2009 1 6 14 22 26
6 E1 216–229 1 6 14 19 26 66 NS5a 2022–2035 1 7 14 22 26
7 E1 246–260 2 8 14 20 26 67 NS5a 2034–2047 1 7 14 22 26
8 E1 262–275 1 6 14 20 26 68 NS5a 2045–2058 1 7 14 22 26
9 E1 283–296 1 7 14 21 26 69 NS5a 2062–2075 1 7 14 22 26
10 E1 307–320 1 7 14 20 26 70 NS5a 2076–2089 1 7 14 22 26
11 E1 310–324 1 7 nd nd nd 71 NS5a 2092–2105 1 7 14 22 26
12 E1 314–326 1 7 nd nd nd 72 NS5a 2121–2134 1 7 14 22 nd
13 E1 330–344 3 7 16 20 26 73 NS5a 2136–2149 1 13 14 22 26
14 E1 345–360 1 7 16 20 28 74 NS5a 2142–2155 1 12 14 22 26
15 E1 361–374 1 7 14 20 26 75 NS5a 2216–2229 1 7 14 22 26
16 E2 403–416 4 9 nd nd nd 76 NS5a 2240–2253 1 nd 14 22 26
17 E2 408–421 2 7 nd nd nd 77 NS5a 2256–2269 1 12 14 22 26
18 E2 456–469 1 10 14 22 26 78 NS5a 2262–2275 1 nd 14 22 26
19 E2 526–539 3 7 14 20 26 79 NS5a 2274–2287 1 12 14 22 26
20 E2 570–583 3 11 14 22 26 80 NS5a 2296–2309 1 7 14 22 26
21 E2 667–681 2 7 14 20 26 81 NS5a 2303–2319 1 13 14 22 26
22 E2 704–717 1 7 14 20 26 82 NS5a 2310–2323 1 13 14 22 26
23 NS2a 758–771 1 9 14 22 26 83 NS5a 2324–2337 1 7 14 22 26
24 NS2a 782–795 1 7 14 22 26 84 NS5a 2336–2349 1 7 17 22 26
25 NS2b 810–823 1 7 14 nd 26 85 NS5a 2343–2356 1 7 18 22 26
26 NS2b 822–835 1 7 14 22 26 86 NS5a 2350–2363 1 7 14 22 26
27 NS2b 836–849 1 7 14 22 26 87 NS5a 2357–2370 1 12 14 22 26
28 NS2b 852–865 1 7 14 22 26 88 NS5a 2364–2377 1 9 14 22 26
29 NS2b 872–885 1 7 14 22 26 89 NS5a 2371–2384 1 7 14 22 26
30 NS2b 896–909 1 7 14 22 26 90 NS5a 2378–2391 1 7 14 22 26
31 NS2b 918–931 1 7 14 22 26 91 NS5a 2400 (Ins1*) nd nd 14 22 nd
32 NS2b 934–947 1 7 14 22 26 92 NS5a 2400 (Ins2*) nd nd 14 22 nd
33 NS2b 978–991 1 11 14 22 26 93 NS5a 2406–2419 1 13 14 22 26
34 NS2b 1012–1025 1 6 14 22 26 94 NS5b 2432–2445 1 12 14 22 26
35 NS3 1052–1065 1 6 14 22 26 95 NS5b 2451–2464 1 12 14 22 nd
36 NS3 1066–1079 1 7 14 22 26 96 NS5b 2478–2491 1 7 14 nd 26
37 NS3 1086–1099 1 7 14 22 26 97 NS5b 2492–2505 1 12 14 22 26
38 NS3 1102–1115 1 7 14 22 26 98 NS5b 2518–2531 1 12 14 22 26
39 NS3 1116–1129 1 6 14 22 26 99 NS5b 2529–2542 2 12 14 22 26
40 NS3 1142–1155 1 nd 14 22 26 100 NS5b 2565–2578 1 nd 14 22 26
41 NS3 1198–1211 1 7 14 22 26 101 NS5b 2598–2611 2 12 14 22 nd
42 NS3 1316–1329 1 7 14 22 26 102 NS5b 2618–2631 1 12 14 22 26
43 NS3 1362–1375 1 7 14 22 26 103 NS5b 2655–2668 1 12 14 22 26
44 NS3 1402–1415 1 7 14 23 26 104 NS5b 2662–2675 1 12 14 20 26
45 NS3 1452–1465 1 nd 14 23 26 105 NS5b 2680–2693 1 12 14 22 26
46 NS3 1494–1507 1 12 14 23 26 106 NS5b 2702–2715 1 nd 14 22 26
47 NS3 1577–1590 1 6 14 22 29 107 NS5b 2720–2733 1 7 16 25 32
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Table 1 (cont.)
Source of sequence Source of sequence
No. HCV region 1a 1b 2a 2b 3 No. HCV region 1a 1b 2a 2b 3
48 NS3 1646–1659 1 nd 14 23 26 108 NS5b 2743–2756 1 12 14 22 26
49 NS4a 1690–1699 5 7 14 24 26 109 NS5b 2792–2805 1 7 14 22 26
50 NS4a 1695–1708 1 12 14 22 26 110 NS5b 2832–2845 1 7 14 22 26
51 NS4b 1714–1727 nd 7 14 22 26 111 NS5b 2850–2863 1 7 14 22 26
52 NS4b 1718–1728 nd nd 14 nd nd 112 NS5b 2862–2865 1 7 14 22 26
53 NS4b 1728–1741 1 7 14 22 30 113 NS5b 2895–2908 1 7 14 22 nd
54 NS4b 1734–1743 nd nd nd nd 26 114 NS5b 2914–2927 1 7 16 22 26
55 NS4b 1744–1757 1 7 14 22 30 115 NS5b 2930–2943 1 7 14 22 26
56 NS4b 1752–1758 nd nd nd nd 26 116 NS5b 2958–2971 1 7 14 22 26
57 NS4b 1794–1807 1 7 14 nd 26 117 NS5b 2968–2981 1 13 14 22 26
58 NS4b 1816–1829 1 7 14 nd 26 118 NS5b 2983–2996 2 7 14 22 26
59 NS4b 1829–1842 1 7 14 nd 26 119 NS5b 2990–3003 2 7 14 22 26
60 NS4b 1868–1881 1 7 14 22 26 120 NS5b 2998–3011 1 7 14 22 26
* Sequences 14 and 22 (as listed in the legend) include a 20 aa insertion at position 2400. Region 91 (Ins1)
corresponds to amino acids 1 to 14 and region 92 (Ins2) corresponds to amino acids 10 to 20 of this
insertion.
The reasons behind this distribution are not well understood,
although it has been postulated recently that the different HCV
genotypes evolved from a common ancestor 500–2000 years
ago (Smith et al., 1997).
Different HCV genotypes may show differences in im-
munogenicity. Thus, antigens from HCV type 1 (used in
commercial ELISA assays), from relatively conserved core and
NS3 protein regions, may recognize serum antibodies from
other genotypes with different sensitivities. For instance, it has
been reported that antigens from these regions of virus
genotype 1 are recognized five times more strongly by sera
from patients infected with virus type 1 than by sera from
those infected with virus genotypes 2 and 3 (Dhaliwal et al.,
1996). Virus genotypes may also influence the response to
interferon-a (IFN-a) therapy. Thus, patients infected with HCV
genotypes 1b and 4 seem to respond less efficiently than those
infected with genotypes 2a, 2b and 3a (Yoshioka et al., 1992 ;
Hino et al., 1994 ; Tsubota et al., 1994 ; Dusheiko et al., 1994 ;
Yamada et al., 1994 ; Hopf et al., 1996). Although it has been
reported that patients infected with virus genotypes 1a and 1b
respond poorly to treatment compared with those infected
with genotypes 2 and 3 (Davis & Lau, 1997), it has also been
suggested that patients infected with genotype 1a may
respond better than those infected with genotype 1b (Lohr et
al., 1996 ; Zein et al., 1996 ; Sakugawa et al., 1997 ; Bell et al.,
1997). However, it is not clear if this enhanced response is
statistically significant. Virus genotype 1b is associated with
hepatic damage and cirrhosis (Pozzato et al., 1994) and is
highly prevalent in patients who require hepatic transplan-
tation (Zein et al., 1995a) and in most cases of hepatocellular
carcinoma (Zein et al., 1995b ; Takada et al., 1996). The
correlation of certain virus genotypes with immunogenicity,
response to IFN-a therapy, cirrhosis and hepatocellular car-
cinoma has prompted several research groups to develop
methods of genotyping the virus. There are at present two
main approaches to assess the genotype of HCV. The first
approach is by reverse transcription of viral RNA from infected
sera and amplification of a region of this RNA either by nested
PCR with genotype-specific primers (Okamoto et al., 1992) or
by using universal primers followed by identification of the
amplified gene either by the pattern of fragments obtained
after digestion with restriction enzymes (Davidson et al., 1995 ;
Mellor et al., 1995 ; Gournay et al., 1995) or by hybridization
with type-specific probes (Viazov et al., 1994). The second
approach uses genotype-specific synthetic peptides to detect
antibodies in the sera of infected patients (Simmonds et al.,
1993 ; Machida et al., 1992 ; Tsukiyama-Kohara et al., 1993 ;
Tanaka et al., 1994). The sensitivity and specificity of the first
approach is higher but it is only available to some laboratories,
whereas the second approach is simpler and can be used in
most laboratories. Although the use of the genotype-specific
synthetic peptides reported by Simmonds et al. (1993) can
identify most virus genotypes, it is unable to distinguish
between subtypes 1a and 1b, which are the most abundant in
the Western world. We speculated that the synthesis of a large
number of synthetic peptides from the most variable regions of
proteins from HCV types and subtypes might give a useful
insight into the relative immunogenicity of HCV proteins from
different genotypes. It might also, at the same time, identify
new type- and subtype-specific peptides for the identification
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Fig. 1. For legend see facing page.
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of genotypes 1, 2 and 3 and for differentiation between
subtypes 1a and 1b. Moreover, a study of the recognition of
this large number of peptides by the sera of HCV-infected
patients with different responses to IFN-a therapy might be
useful to predict response or non-response to this cytokine.
Our findings in these areas are discussed.
Methods
+ Peptides and peptide synthesis. We synthesized 543 peptides
from 120 regions of HCV proteins. These peptides were chosen after
comparing 15 complete and 172 incomplete published HCV sequences
corresponding to different genotypes. The exact locations of these 120
regions within the different proteins from genotypes 1a, 1b, 2a, 2b and
3 are given in Table 1. The peptides were selected from regions with
important sequence diversity among genotypes, but with low or no
diversity within the same type or subtype. Peptides were synthesized by
the solid-phase method of Merrifield (1963) using the Na-9-fluor-
enylmethoxycarbonyl (Fmoc) alternative (Atherton et al., 1981) and a
multiple solid-phase peptide synthesizer (Borra! s-Cuesta et al., 1991). In
most cases, the peptides contained 15 amino acids and were all
synthesized with an Ala at the C terminus for ease of synthesis. The
peptides were used without further purification. Linear peptide homo-
polymers were prepared from side-chain-protected peptide monomers as
described previously (Borra! s-Cuesta et al., 1988). In brief, the peptide
(5 lmol) was dissolved in 200 ll dimethylformamide (DMF) and the
apparent pH was adjusted to pH 8–9 with N-ethyl morpholine (the pH
was controlled by adding a drop of the solution on a wet piece of
indicator paper). This solution was stirred during the addition of 5 lmol
dicyclohexylcarbodiimide and 5 lmol 1-hydroxybenzotriazole dissolved
in 100 ll DMF. After 48 h at room temperature, the reaction mixture was
purified by gel filtration on a column of Sephadex LH-20 (Pharmacia)
equilibrated in DMF. The polymers, recovered from the first peak, were
dried under high vacuum and the amino acid side-chains were deprotected
by treatment with 95% trifluoroacetic acid and scavengers. Peptides were
precipitated with diethyl ether, dissolved in water and freeze-dried. The
polymers thus obtained were used without further purification.
+ Patients. Four panels of sera from non-treated, HCV-infected
patients and a panel of sera from healthy blood donors were used. The
first panel consisted of 90 sera from our serum library (13, 46, four and
27 sera of patients infected with HCV genotypes 1a, 1b, 2 and 3,
respectively). The second panel consisted of 101 sera from the Instituto
Nacional de la Nutricio! n Salvador Zubira! n, Mexico (13, 69, 16 and three
sera of patients infected with HCV genotypes 1a, 1b, 2 and 3,
respectively). The third panel contained another 54 sera from our serum
library (14, 17, four, 15 and three sera of patients infected with HCV
Fig. 1. Peptides from variable regions of HCV proteins from genotypes 1a, 1b, 2a, 2b and 3 and their recognition by the first
panel of 90 HCV-infected sera. (A) Diagram of the location of 120 regions (vertical lines) within the HCV proteins from which
peptides were synthesized. (B) Peptides from a given genotype were tested against sera from the same genotype as well as
against sera from the remaining genotypes and a panel of 35 sera from healthy donors (HD). Abscissa : position of the 120
variable regions (the location of peptides within the different HCV proteins is given in Table 1). Ordinate : percentage of sera
recognizing the peptide. (*) Peptide was not synthesized ; (#) the sequence of peptides from genotypes 1a and 1b or 2a and
2b are identical. (MR) Mean recognition of peptides (see text). The genotype of the sera is indicated at the right-hand side of
the figure.
genotypes 1a, 1b, 2, 3 and 4, respectively). The fourth panel contained 14
sera from patients coinfected with different virus genotypes (four, five,
three, one and one sera coinfected with HCV genotypes 1a›1b, 1b›4,
1b›2, 1a›3 and 2›3, respectively). All sera were positive against a
third-generation ELISA (Ortho Diagnostics) and HCV RNA-positive by
PCR. The fifth panel consisted of 35 sera from healthy blood donors with
no clinical symptoms of hepatitis and without anti-HCV antibodies in
their sera.
In order to correlate antibody peptide recognition with the outcome
of IFN-a therapy, we tested the peptides by ELISA against the sera of 67
patients from the first panel, who were later submitted to IFN-a therapy
as described by Gavier et al. (1997). The outcome of this therapy was : 34
sustained responders, six transient responders and 27 non-responders.
We considered a patient as a sustained responder when, after treatment,
their alanine aminotransferase level remained within the normal range
(1–22 UI}l in women and 1–29 UI}l in men) and serum HCV RNA was
persistently negative during the whole follow-up period (minimum
follow up, 18 months). Transient responders were those who responded
to IFN-a therapy but relapsed after IFN-a withdrawal. All other patients
were considered as non-responders (Gavier et al., 1997).
+ Detection of anti-peptide antibodies by ELISA. Anti-HCV
antibodies in the sera were detected by ELISA with synthetic peptides.
Microtitre wells were coated by overnight incubation at 4 °C with 50 ll
peptide solution (40 lg}ml peptide in 0–1 M sodium carbonate buffer,
pH 10–5). Wells were then washed three times with 200 ll per well of a
solution of PBST (2 mM KH
#
PO
%
, 8 mM Na
#
HPO
%
, 140 mM NaCl,
0–1% Tween 20, pH 7–6). To block non-specific antibody binding, the
wells were incubated with 300 ll per well PBSTM (PBST containing 1%
powdered milk) for 1 h at room temperature. The wells were washed
three times with 200 ll per well PBST and then 50 ll serum, diluted 1 :20
in PBSTM, was added and incubated at 37 °C for 1 h. Wells were washed
three times with 200 ll per well PBST and then incubated at 37 °C for 1 h
with 50 ll of a solution of biotinylated goat anti-human IgG whole
antibody (Amersham) diluted 1 :1000 in PBSTM. After washing three
times with 200 ll per well PBST, wells were incubated at 37 °C for 1 h
with 50 ll of a solution of horseradish peroxidase–streptavidin
(Amersham) diluted 1 :500 in PBSTM. After washing three times with
PBST, the colour reaction was started by adding 100 ll of a solution
prepared by mixing 10 ml 0–6% acetic acid (pH 4–7), 7–5 ll 33% (w}v)
hydrogen peroxide and 100 ll of a 40 mM aqueous solution of 2,2«-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid). After 1 h the ab-
sorbance was read at 405 nm in a Titretek Multiskan MKII. A serum was
considered positive by ELISA against a peptide when the absorbance
corresponding to this serum was at least twice the mean value of the 30
peptides giving the lowest absorbance within the same ELISA plate. The
cut-off value thus obtained was similar for HCV-infected sera and for
healthy sera.
+ PCR amplification of serum HCV RNA and HCV genotyping.
HCV RNA was extracted from 100 ll serum by using the Ultraspec-RNA
(Biotecx) extraction solution. Reverse transcription and nested PCR were
carried out basically as described previously by Garson et al. (1990), but
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Table 2. Examples of the effect of sequence displacement, shortening of peptides and
substitution by Ala on peptide recognition by sera from patients infected with different
HCV genotypes
Alanine residues included in peptides that are not contained in the wild-type sequence are indicated by A.
Modified peptides are indicated by the suffix (mp). –, Not detected.
Recognition by sera (%)
Genotype
Amino acid sequence Region of polyprotein of peptide 1a 1b 2 3 Controls
(i) Sequence displacement
RAALIEEGQRIAEMA NS4b 1714–1727 2a – 2 – 4 3
ASRAALIEEGQRIA NS4b 1712–1724 (mp) 2a – – 75 – –
HLPYIEQGMQLAEQA NS4b 1714–1727 1a,1b 38 65 25 4 –
YIEQGMMLAEQFKQA NS4b 1717–1730 (mp) 1a – 6 – 4 –
CSQHLPYIEQGMMLA NS4b 1711–1725 (mp) 1a 92 85 25 37 14
(ii) Shortening of peptides
EEDEREISVPAEILA NS5a 2262–2275 1a,1b 61 26 – – 3
AAEISVPAEILAAA NS5a 2267–2275 (mp) 1a 23 – – – –
ACKPLLREDVTFQVA NS5a 2136–2149 1b 15 26 – 18 3
AAAADVTFQVAAAA NS5a 2144–2149 (mp) 1b 61 35 75 37 26
RRLHQWISSECTTPA NS4b 1958–1971 1a 23 6 – – 3
AAQWISSECTTPAA NS4b 1962–1971 (mp) 1a – – – – –
KRLHQWINEDCSTPA NS4b 1958–1971 1b 15 26 25 11 –
AAKRLHQWINEDAA NS4b 1958–1967 (mp) 1b – 6 – 11 –
AAQWINEDCSTPAA NS4b 1962–1971 (mp) 1b – – – – –
RRLHNWITEDCPIPA NS4b 1958–1971 2a – 6 75 – –
AANWITEDCPIPAA NS4b 1962–1971 (mp) 2a – 2 50 – –
RRLHAWITEDCPVPA NS4b 1958–1971 2b – 4 75 11 3
AAAWITEDCPVPAA NS4b 1962–1971 (mp) 2b – – 50 – –
RRLHQWINEDYPSPA NS4b 1958–1971 3a – 6 75 48 –
AAAAEDYPSPAAAA NS4b 1966–1971 (mp) 3a – – – 11 –
(iii) Substitution by Ala
FKQKALGLLQTASRA NS4b 1728–1741 1a 61 48 – 18 –
AAQAALGLLQTASRA NS4b 1728–1741 (mp) 1a 8 4 – – –
PLLDRWKAPDYVPPA NS5a 2296–2309 3a 15 35 25 44 –
PAADRAAAPDAVAAA NS5a 2296–2309 (mp) 3a – – 25 – –
EEDEREISVPAEILA NS5a 2262–2275 1a,1b 77 24 – – 3
AEDAAEISVPAEILA NS5a 2262–2275 (mp) 1a 15 15 – 11 23
with the two sets of primers for the 5« untranslated region of HCV
genome described by Larrea et al. (1996). The limit of sensitivity of this
assay was 1000 copies HCV genome per ml.
Genotypes were determined by RT–PCR of a core region from HCV,
followed by hybridization with genotype-specific probes, as described by
Viazov et al. (1994) and modified by Larrea et al. (1996) and Gavier et al.
(1997).
+ Statistical analysis. Differences in peptide recognition by sera
were tested by using the Mann–Whitney non-parametric test.
Results
In order to study the immunogenicity of variable regions
from HCV proteins and to attempt to differentiate between
HCV types and subtypes by ELISA, we compared 187 HCV
sequences and selected 543 peptides from 120 regions (Table
1 and Fig. 1A) that had little or no sequence variability within
a given subtype and maximal variability between types and
subtypes. These 543 peptides were synthesized and tested by
ELISA against the 90 sera from HCV-infected patients from the
first panel and against the 35 sera from healthy donors from the
fifth panel (Fig. 1B). An analysis of Fig. 1 shows that peptides
were recognized according to one of the following patterns : (i)
by none of the sera, 179}543 (33%) ; (ii) non-specifically,
recognized by one or more healthy controls, 171}543 (31–5%) ;
and (iii) specifically, only recognized by the sera of HCV-
infected patients, 193}543 (35–5%). Among group (iii), 39}193
(20–2%) were genotype-specific. Moreover, of these 39
genotype-specific peptides, five, 12, 14, two and six were
specific for genotypes 1a, 1b, 1, 2 and 3, respectively.
To gain an insight into the relative immunogenicity of
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Table 3. Effect of polymerization on peptide recognition by sera of patients infected with
different HCV genotypes
Recognition by sera (%)
Genotype
Region of polyprotein of peptide Polymerization 1a 1b 2 3 Controls
NS5a 2267–2275 1a Monomer 7–3 – – – –
Polymer 19–5 5–3 – – –
NS5a 2274–2287 1a Monomer 2–4 – – – –
Polymer 4–9 – – – –
NS5a 2350–2363 1a Monomer 19–5 – – – 2–8
Polymer 24–4 – – – –
NS4b 1744–1757 1b Monomer – 19–7 – – –
Polymer – 20–4 – – –
NS3 1086–1099 1b Monomer 2–4 3–8 – 2–2 –
Polymer 2–4 4–5 – – –
NS5a 2121–2134 1b Monomer – 3–8 – – –
Polymer – 5–3 – – –
–, Not detected.
HCV proteins from genotypes 1a, 1b, 2a, 2b and 3, we
calculated the mean recognition of peptides of a given
genotype by the sera of patients infected with various
genotypes. Thus, the average recognition of peptides from
genotype 1a by the sera of patients infected with genotype 1a
was calculated by adding the percentage recognition of all 1a
peptides and dividing by their number. In this way, a mean
value of 9–3 was obtained (shown at the right side of Fig. 1). All
other mean recognition values were calculated in an analogous
manner (Fig. 1). The mean recognition of peptides 1a, 1b, and
3 by sera infected with genotypes 1a, 1b and 3, respectively,
showed no significant differences. It was found that sera from
one genotype recognized peptides from the same genotype
but also from other genotypes. This cross-recognition was
significantly similar between genotypes 1a, 1b and 3. No
statistical comparison with peptides from genotypes 2a and 2b
could be carried out because only four sera from the first panel
were available from this genotype.
From Fig. 1, it is clear that the greatest number of variable
regions was located in NS5a and that the most immunogenic
regions were found in proteins NS4a, NS4b and NS5a. Some
regions were found to be more immunogenic in certain
genotypes. Thus, region 25 (NS2b) was more immunogenic in
genotype 3 than in genotypes 1 and 2. Region 49 (NS4a) was
immunogenic in genotypes 2 and 3 but not in genotype 1.
Regions 53 (NS4b), 71 (NS5a) and 77 (NS5a) were immuno-
genic in genotypes 1 and 3 but not in genotype 2. Region 63
(NS4b) was better recognized by genotypes 2 and 3 than by
genotypes 1a and 1b. Region 75 (NS5a) was immunogenic in
genotypes 1a, 2 and 3 but not in genotype 1b. Region 78
(NS5a) was much more immunogenic in genotypes 1a and 2
than in genotype 3. Finally, region 81 (NS5a) was more
immunogenic in genotypes 1a and 3 than in genotypes 1b
and 2.
We investigated a possible correlation between peptide
recognition and response to IFN-a therapy. This was done by
studying the recognition of all 543 peptides by the sera of 67
patients from the first panel, for whom the outcome of IFN-a
therapy was known. No correlation was found between
recognition of any of the peptides and the outcome of therapy.
In order to attempt to develop a large number of genotype-
specific peptides to assess HCV genotypes by ELISA, we
modified 70 peptides that cross-reacted either with the sera of
healthy controls (34 peptides) or with sera from other
genotypes (36 peptides). Three types of modifications were
carried out : (i) displacement of the sequence towards the N or
C terminus ; (ii) shortening the peptide ; and (iii) substitution of
some amino acids from the sequence with Ala. These
modifications gave a total of 116 peptides. Using the first panel
of 90 sera, it was found that these modifications led to the
following effects : increase of peptide specificity, loss of
recognition or appearance of cross-reactivity with healthy
controls. Table 2 shows examples of these results. Of these 116
modified peptides, 21 (18–1%) were rendered genotype-
specific.
In order to improve the sensitivity of the genotype-specific
peptides, we carried out homopolymerization of the most
relevant ones. Thus, we selected the 21 genotype-specific
peptides obtained after modification, as well as 22 peptides
from the group of 39 genotype-specific peptides that were able
to recognize 4% or more of the sera. These 43 peptide
monomers afforded 39 homopolymers ; yields of the four
remaining homopolymers were too low to be used in
experimental work. Homopolymerization of peptides had
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Table 4. Peptides from HCV proteins used to assess HCV genotypes by ELISA
Peptide homopolymers are indicated in parentheses. Modified peptides are indicated by the suffix (mp).
Alanine residues added that are not contained in the wild-type sequence are indicated by A.
Genotype
Peptide Amino acid sequence Region of polyprotein Peptide Assessed
1 AAEISVPAEILAAA NS5 2267–2275 (mp) 1a 1a
2 ILRKSRRFAQALPVA NS5a 2274–2287 1a 1a
3 (ILRKSRRFAQALPVA)
n
NS5a 2274–2287 1a 1a
4 (RSFGSSSTSGITGDA)
n
NS5a 2350–2363 1a 1a
5 SSIVYEAADMIMHTA E1 210–223 1b 1b
6 YIEQGMQLAEQFKQA NS4b 1717–1730 (mp) 1b 1b
7 EAAAPVVESKWRALA NS4b 1744–1757 1b 1b
8 (EAAAPVVESKWRALA)
n
NS4b 1744–1757 1b 1b
9 FFTEVDGVRLHRYAA NS5a 2121–2134 1b 1b
10 (FFTEVDGVRLHRYAA)
n
NS5a 2121–2134 1b 1b
11 PLLESWKDPDYVPPA NS5a 2296–2309 1b 1b
12 AAVPPPRRKRTVVAA NS5a 2324–2334 (mp) 1b 1b
13 AAAYEATDMIMAAA E1 214–221 (mp) 1b 1
14 (GSKTLAGPKGPITQA)
n
NS2b 1086–1099 1b 1
15 EECSQHLPYIEQGMA NS4b 1709–1722 (mp) 1a 1
16 HLPYIEQGMMLA NS4b 1714–1725 (mp) 1a 1
17 HLPYIEQGMQLA NS4b 1714–1725 (mp) 1b 1
18 (HLPYIEQGMQLA)
n
NS4b 1714–1725 (mp) 1b 1
19 (YIEQGMQLAEQFKQA)
n
NS4b 1717–1730 (mp) 1b 1
20 AAQAALGLLQTASRA NS4b 1728–1741 (mp) 1a 1
21 QKALGLLQTASRQA NS4b 1730–1742 (mp) 1a 1
22 AAALGLLQTASRAA NS4b 1732–1741 (mp) 1a 1
23 AAALGLLQTATKAA NS4b 1732–1741 (mp) 1b 1
24 (AAAREDVTFQVAAA)
n
NS5a 2142–2149 (mp) 1b 1
25 (TANHDSPDAELIEAA)
n
NS5a 2216–2229 1a 1
26 (AAEISVPAEILAAA)
n
NS5a 2267–2275 (mp) 1a 1
27 KKRTVVLTESTLSTA NS5a 2329–2343 (mp) 1a 1
28 TESTVSSALAELATA NS5a 2336–2349 1b 1
29 ALAELATRSFGSSSA NS5a 2343–2356 1a 1
30 (ALAELATRSFGSSSA)
n
NS5a 2343–2356 1a 1
31 KTFGSSGSSAVDSGA NS5a 2350–2363 1b 1
32 PDSDAESYSSMPPLA NS5a 2378–2391 1a 1
33 EECASRAALIEEGQA NS4a 1709–1722 (mp) 2a 2
34 ASRAALIEEGQRIA NS4a 1712–1724 (mp) 2a 2
35 ASKAALIEEGQRMA NS4a 1712–1724 (mp) 2b 2
36 ERSDLEPSIPSEYMA NS5a 2262–2275 2a 2
37 AAAWITEDYPSPAA NS4b 1963–1871 (mp) 3a 3
38 QTHRPHPDAELVDAA NS5a 2216–2229 3a 3
39 FEPLRAETDDVEPSA NS5a 2256–2269 3a 3
40 TAASRAAGLKDPSFA NS5b 2720–2733 3b 3
similar effects to those described above for peptide mono-
mers. In Table 3, we give some examples of the effect of
homopolymerization.
The 43 peptide monomers and the 39 homopolymers were
tested against the five panels of sera described in Methods.
This allowed the selection of 40 genotype-specific peptides
(Table 4). The recognition of these peptides by the first three
panels of HCV-infected sera shows that peptides 1 to 12 were
able to differentiate between subtypes 1a and 1b whereas
peptides 13 to 40 were only able to differentiate between types
1, 2 and 3 (Table 4 and Fig. 2A). The sensitivities of assessment
of genotypes 1a, 1b, 1, 2 and 3 were 34–1, 48–5, 68–8, 58–3 and
48–9%, respectively, with specificities of 100, 99–1, 97–1, 99–5
and 99% (Fig. 2B). The overall sensitivity and specificity of the
assessment of genotypes 1, 2 and 3 were 64 and 98%,
respectively.
We also studied genotype assessment in the 14 sera of the
fourth panel, which were coinfected with two HCV genotypes.
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Fig. 2. Recognition of the 40 selected peptides (Table 4) by sera from the
first three panels of patients infected with HCV. (A) Peptides 1–4 from
genotype 1a, 5–12 from genotype 1b, 13–32 from genotype 1a or 1b,
33–36 from genotype 2 and 37–40 from genotype 3 (indicated by
horizontal arrows) were used to assess genotypes 1a, 1b, 1, 2 and 3,
respectively, in the sera of patients infected with HCV genotypes 1a, 1b, 2
and 3 (indicated at the right-hand side of the figure). (B) Overall
sensitivity (filled bars) and specificity (empty bars) of genotype
assessment by the different groups of peptides.
It was found that both genotypes could be assessed correctly
in two cases. Only one genotype was assessed in four cases.
Neither of the genotypes could be assessed in seven cases. The
virus genotype was incorrectly assessed in one case.
Four sera from HCV-infected patients from our serum
library, which were PCR negative and could not be genotyped
by hybridization with genotype-specific DNA probes, were
tested against the 40 peptides from Table 4. This allowed the
assessment of the virus genotype in two of the four sera tested.
Discussion
As shown in Fig. 1 and Table 1, a great number of peptides
from variable regions of HCV proteins was synthesized in
order to identify genotype-specific peptides. No peptides from
the hypervariable region of surface protein E2 were synthe-
sized, because sequence variability within this region was so
high that no consensus sequence could be attributed to a given
genotype.
It was found that the number of peptides from genotypes
1a, 1b, and 3 recognized by the corresponding sera, as well as
the mean recognition of peptides by the sera, were not
significantly different among genotypes. These findings sug-
gest that the overall immunogenicity of variable regions of
HCV proteins from these genotypes is likely to be similar.
Some peptides from a given genotype were not recognized
by sera from patients infected with this genotype. However,
the sera from patients infected with other genotypes cross-
reacted with these peptides and recognized the equivalent
peptide from their own genotype with higher intensity. This
result may be explained by assuming that a region from a
protein may be immunogenic in one genotype but not in
others ; i.e. peptide 1a from region 49 was not recognized by
sera from patients infected with HCV genotype 1a, but was
recognized by the sera from patients infected with genotype 3
(Fig. 1B).
It is interesting to note that 27 of the 40 peptides (67–5%)
finally selected to assess HCV genotypes were either modified
peptides and}or homopolymers, showing that a first selection
of peptides based on some amino acid differences was, in many
cases, not sufficient to guarantee good specificity and sen-
sitivity. Indeed, from Table 2 and other data not shown, it was
found that several epitopes could be found within a sequence
of 14–15 amino acids, which may account for the relatively
high percentage of cross-reactivity.
Peptide shortening experiments, like the ones shown in
Table 2, suggest that B-cell epitopes in the same protein from
different HCV genotypes might be located in slightly different
positions. This is probably due to preferential antibody
recognition of certain topologies in proteins of similar
sequence. Thus, since the amino acid sequence affects the fine
three-dimensional structure of the protein, certain sequences
are likely to be more antigenic than others.
It was found that not all sera from patients infected with the
same HCV genotype recognized the same peptides. This
might be due to differences in the B-cell repertoire of the
patients or to preferential activation of B lymphocytes of
different specificities. In this last case, the explanation might be
related to the class II molecules of patients. Thus, presentation
of certain peptides in conjunction with class II molecules of the
patient by the antigen-presenting cells would be responsible
for providing T-cell help to a given B lymphocyte specific for
a B-cell epitope. Since these helper peptides are class II
restricted, some B-cell epitopes, but not others, would be
potentiated.
The percentage of peptides that was recognized by at least
one serum from the fifth panel of 35 healthy blood donors was
31–5% (Fig. 1). This might be a reflection of the great number
of antigens to which we are exposed during our lives, but it
may also be related to the high rate of mutation of HCV in
response to immune pressure and to the relatively small
number of amino acids that define a B-cell epitope (probably
around 5–7 amino acids). Moreover, the large panel of peptides
that we had to use to cover the different HCV genotypes
greatly enhanced the probability of detecting cross-reactivity.
The way a peptide is presented in the ELISA plate may have
important effects on the sensitivity and specificity of antibody
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detection. In this work, homopolymerization rendered some
peptides either non-reactive or less specific but, as shown in
Table 3, it also enhanced the sensitivity and}or specificity of
others. We used homopolymerization because we had pre-
viously shown (Sarobe et al., 1994) that immunization with
homopolymers rendered peptides more immunogenic, sug-
gesting better presentation of B-cell epitopes by homo-
polymers.
The sensitivity of assessment of genotypes 1, 2, 3, 4, 5 and
6 by using synthetic peptides according to the method of
Simmonds et al. (1993) has been reported to be 89% (Pawlotsky
et al., 1997). Using the same method, Cerino et al. (1996),
Brechot (1996), Agence du Me! dicaments, France (1996), van
Doorn et al. (1996), Forns et al. (1996) and Martinot-Peignoux
et al. (1995) reported sensitivities of 51, 80, 82, 83, 85 and 91%,
respectively. With the exception of Cerino et al. (1996), these
values are higher than the 64% sensitivity of genotype
assessment of the method reported here to distinguish between
genotypes 1, 2 and 3. However, to our knowledge, no
serological method has been published that can differentiate
between subtypes 1a and 1b, as in the present study.
In spite of the great number of peptides from variable
regions of HCV proteins used in the present study, the
sensitivity of our method of assessment of genotypes 1, 2 and
3 and subtypes 1a and 1b is still not high enough to match
genotype assessment by PCR techniques. However, because of
its simplicity, our method could be used to assess the genotype
of the virus in an important proportion of sera, and PCR
techniques (which are more complicated and require skilled
personnel) could then be used if assessment was not possible
with peptides. When a serum is HCV-negative by PCR, and
consequently cannot be genotyped by PCR techniques, our
method can be very useful. Indeed, by using genotype-specific
peptides we were able to assess the virus genotype in two of
the four sera that were HCV-negative by PCR. We are at
present studying constant regions of HCV proteins, in the
hope that some of them might be preferentially immunogenic
in certain genotypes. Also, we are carrying out competition
experiments to eliminate unwanted reactions. Preliminary
results show that blocking non-specific cross-reactivity with
peptides from the same region but belonging to other
genotypes may work for some but not all of the sera tested.
This result suggests caution when using this strategy to block
cross-reactivity.
This work was supported by grants from the Gobierno of Navarra
(grant no. 1257}93) ; C.I.C.Y.T. BIO94-0245 and PIUNA from University
of Navarra.
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